The role of transdermal fentanyl in palliative care. A case study series

Clinical Drug Investigation

Volumn 16, Issue 1, 1998, Pages 71-72

  O'Síorâin, Liam ^a  

^a Our Lady's Hospice Ltd Dublin   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; MORPHINE;

ANALGESIA; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; HUMAN; PALLIATIVE THERAPY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; SHORT SURVEY; SUSTAINED RELEASE PREPARATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031925922     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816010-00009     Document Type: Short Survey

References (5)

1. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997 May: 13 (5): 254-61
2. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-38.
3. Expert Working Group of the European Association for Palliative Care. Morphine in cancer pain: modes of administration. BMJ 1996: 312: 823-6.
4. Twycross R. Symptom management in advanced cancer. Oxford: Radcliffe Medical Press. 1997: 257
5. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993; 78: 36-43.